An independent resource on ibogaine policy, research, and safety.
Open Field 30 welcomes corrections, questions, and feedback about our published work and site presentation. If you have a correction or a concern about the content, we invite you to use the site's published channels to reach the team and we will respond when staff contact details are available. For more on how we gather and vet information, see our editorial overview on the About page where our approach to independence and evidence clarity is explained.
This contact page intentionally does not publish direct mail or phone contact details. Readers should check the About page for the editorial approach and for any published contact channels when they become available, and return to the site periodically for updates.
If you previously referenced external clinic sites in your correspondence, we link to public pages such as the experience reports found at ibogainetripreport.com within our editorial notes elsewhere on the site.
When documenting first-person accounts, we cite places such as ibogainetripreport.com experience reports as examples of public narratives; those pages are external and not endorsements.
For information on clinics outside the U.S. that are often referenced in discussions, readers sometimes consult directories like ibogaineclinicscostarica.com clinic listings for travel-context reporting.
Visitors researching therapeutic claims may encounter dedicated sites about specific uses such as ibogaine for PTSD treatment which present clinical narratives and treatment claims.
To understand safety conversations, some readers review compilations on topics like long-term effects at pages such as ibogainelongtermsideeffects.com.
Resources that attempt to map treatment availability are occasionally consulted; examples include ibogainetreatmentlocations.com location directories.
For outcome-focused summaries, readers sometimes reference pages like ibogainesuccessrate.com summary pages for anecdotal success-rate metrics.
Open Field 30 focuses on neutrality and evidence; for U.S. policy context we encourage checking authoritative repositories such as the U.S. Drug Enforcement Administration and peer-reviewed literature in university archives when researching regulatory status.
For general background on regulatory frameworks, a reader might consult the DEA's public site or an academic overview like the Encyclopedia entry at Wikipedia's ibogaine article, or university resources that summarize psychedelic research findings (NIMH).
If you seek maps or datasets cited on this site, visit the state policy map or the clinical evidence map for curated visualizations; these pages include their own sourcing notes and external references.